PMID- 32995955
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20211112
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 146
IP  - 12
DP  - 2020 Dec
TI  - Prognostic role of regulatory T cells in lymphoma: a systematic review and 
      meta-analysis.
PG  - 3123-3135
LID - 10.1007/s00432-020-03398-1 [doi]
AB  - PURPOSE: The regulatory T cells (Tregs) are a subpopulation of lymphocytes that 
      suppress the immune responses. The prognostic value of Tregs in lymphoma patients 
      remains controversial. Thus, we conducted this meta-analysis to clarify the role 
      of Tregs in the prognosis of lymphoma patients. METHODS: We searched PubMed, 
      Embase, and Web of Science to obtain eligible studies that evaluated the 
      prognostic factor of Tregs for lymphoma patients. Hazards ratios (HRs) with the 
      matching 95% confidence intervals (95%CIs) were merged to estimate the prognostic 
      value of Tregs. RESULTS: We finally retrieved 23 eligible studies, including a 
      total of 2269 patients. The overall pooled analysis on all types of lymphomas 
      showed that Tregs had a significantly positive association with prolonged overall 
      survival (OS) (HR = 0.633, 95% CI 0.528-0.758) and progression-free survival 
      (PFS) (HR = 0.451, 95% CI 0.261-0.779). Subgroup analysis indicated that high 
      Tregs were significantly correlated with longer OS in Hodgkin lymphoma, diffuse 
      large B cell lymphoma, and natural killer/T cell lymphoma. However, there was no 
      significant association of Tregs with T cell lymphoma and follicular lymphoma. 
      CONCLUSIONS: Increased Tregs indicates a better prognosis for patients with 
      lymphoma. Tregs could be used as a valuable prognostic biomarker of lymphoma 
      patients.
FAU - Peng, Fei
AU  - Peng F
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, 
      Hubei, China.
FAU - Qin, You
AU  - Qin Y
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Mu, Shidai
AU  - Mu S
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, 
      Hubei, China.
FAU - Li, Jingwen
AU  - Li J
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, 
      Hubei, China.
FAU - Ai, Lisha
AU  - Ai L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, 
      Hubei, China. ailisha86@126.com.
FAU - Hu, Yu
AU  - Hu Y
AUID- ORCID: 0000-0002-2815-4568
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, 
      Hubei, China. dr_huyu@126.com.
AD  - Collaborative Innovation Center of Hematology, Huazhong University of Science and 
      Technology, Wuhan, 430022, China. dr_huyu@126.com.
LA  - eng
GR  - No 81500172/National Natural Science Foundation of China/
GR  - No 81202962/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200929
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Hodgkin Disease/*drug therapy/immunology/pathology
MH  - Humans
MH  - Lymphocytes/immunology/pathology
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/immunology/pathology
MH  - *Prognosis
MH  - Progression-Free Survival
MH  - T-Lymphocytes, Regulatory/*immunology/pathology
OTO - NOTNLM
OT  - Lymphoma
OT  - Meta-analysis
OT  - Prognosis
OT  - Regulatory T cells
EDAT- 2020/10/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/30 06:17
PHST- 2020/07/22 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/30 06:17 [entrez]
AID - 10.1007/s00432-020-03398-1 [pii]
AID - 10.1007/s00432-020-03398-1 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2020 Dec;146(12):3123-3135. doi: 
      10.1007/s00432-020-03398-1. Epub 2020 Sep 29.